Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Phase 2 study of VX-152 combination drug in people with cystic fibrosis. , protocol number Vertex VX-152-102

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 1/2 Study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis. , protocol number Proteostasis Therapeutics NCT03140527 PTI-801-01

    This study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug PTI-801

    • Age:

      18 years and over

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      8

    • Length of Participation:

      30

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis. , protocol number NCT02953314 VERTEX VX15-661-113

    This study evaluated the safety and tolerability of the drug Tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) in children with CF. This study was for children who have two copies of the F508 del mutation or one copy of F508del and a second mutation that is either residual function or results in a gating defect and responds to ivacaftor.

    • Age:

      6-11 years

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      28 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease , protocol number NCT00163696

    Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique

    • Age:

      18-65 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: USA

    Viral pathogenisis of early cystic fibrosis lung disease , protocol number NCT01973192 1R01HL116211-01

    Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

    • Age:

      2-4 months

    • Mutation(s):

      Hetrozygous

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-IP-15 NCT02781610

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      3

    • Length of Participation:

      35 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US (healthy volunteers) & Belfast (CF)

    Phase 2 Study of PTI-808 and triple combination therapy in adults with cystic fibrosis , protocol number NCT03500263 PTI-808-01 Proteostasis

    This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del or One Copy F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      56 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number NCT02564354 ProQR PQ-010-002

    This study evaluated the effectiveness of the drug eluforsen (when sprayed in the nose) to improve nasal cell chloride transport. This study was for people with CF who have at least one copy of the F508del CFTR mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number NCT02589236 NIVALIS N91115-2CF1-05

    This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of F508del CFTR mutation and were also taking lumacaftor/ivacaftor (Orkambi®).

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 85%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Displaying results 121-130 (of 194)
     |<  <  9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18  >  >|